Acute and chronic cerebrovascular metabolic disorders resulting from atherosclerosis, thrombosis and embolism of cerebral vessels; transient disorders of cerebral circulation (transient ischemic attacks).
As additional therapy for systemic arterial hypertension.
Sermion (nicergoline) coated tablets 30 mg. №30
active substance: nicergoline;
1 tablet contains nicergoline 30 mg;
auxiliary substances: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, magnesium stearate, sodium carboxymethyl cellulose, hydroxypropyl methyl cellulose, titanium dioxide (E 171), polyethylene glycol 6000, iron oxide yellow (E 172), silicone.
The main physical and chemical properties: round biconvex tablets covered with an opaque yellow film shell.
Means affecting the cardiovascular system. Peripheral vasodilators. Horn alkaloids. Nicergoline.
ATX code C04A E02.
Nicergoline is an ergoline derivative with alpha-1-adrenergic blocking activity when administered parenterally. After oral administration, nicergoline undergoes rapid and significant metabolism with the formation of a number of metabolites, due to which activity is also observed at various levels of the central nervous system.
When administered orally, Sermion exhibits numerous neuropharmacological effects: it not only increases the intake and consumption of glucose in the brain, enhances the biosynthesis of protein and nucleic acids, but also affects various neurotransmitter systems.
Sermion is used in the treatment of acute and chronic cerebral vascular and metabolic disorders caused by atherosclerosis, arterial hypertension, thrombosis or cerebral vascular embolism, including dementia of vascular etiology, acute transient cerebrovascular accidents and circulatory disorders.
The drug is used in the treatment of acute and chronic peripheral vascular and metabolic disorders: Raynaud’s disease, functional and organic arteriopathies of the extremities, conditions caused by impaired peripheral blood flow.
In addition, Sermion is used in the complex treatment of hypertensive crises.
Acute bleeding, severe bradycardia, orthostatic hypotension, acute myocardial infarction, pregnancy and lactation period, intolerance to the components of the drug are considered absolute contraindications to the appointment of Sermion. In addition, Sermion tablets are not prescribed for patients with fructose intolerance, isomaltase or sucrase deficiency, glucose-galactose malabsorption, as well as for persons under 18 years of age.
A relative contraindication to the use of Sermion is gout, a history of hyperuricemia. So, care should be taken when prescribing a drug to patients who are taking drugs that cause metabolic disturbances and excretion of uric acid.
Application during pregnancy and lactation
The use of Sermion in the therapy of nursing and pregnant women is possible only in extreme cases, since the safety profile of nicergoline for this category of patients is unknown. The use of Sermion in the treatment of nursing and pregnant women is carried out only under strict medical supervision.
Method of administration and dosage
Sermion tablets are intended for oral administration. In the absence of other recommendations, the drug is taken 3 times a day from 30 mg twice a day. It is very important to observe equal time intervals between taking the drug. Sermion is intended for long-term treatment.
Even when Sermion is taken in doses significantly higher than therapeutic, patients do not have any negative symptoms, with the exception of a short-term decrease in arterial pressure.
When taking Sermion, the development of side effects is very rarely observed. Sometimes, with prolonged use of the drug, patients may experience a decrease in blood pressure, cold extremities, dizziness, weakness, sweating, dyspeptic disorders, increased acidity of gastric secretions, sleep disturbances and allergic skin reactions.